BioStem Technologies closed at $1.04 on Nov 5, down 9.57%, within 0.0% of its lowest close since Sep 11. Volume of 197.2K shares was 1.16× its 20-day average (close to normal).
Split-adjusted performance: -56.5% over one month.
Short interest was 333.8K shares at the Oct 15 settlement, up 239.1% from the prior report (2.3% of float, 3.0 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| BSEMBioStem Technologies | $1.04 | −9.57% | — | — | — | — | $19.4M | |
| BKHABlack Hawk Acquisition | $4.50 | −19.21% | — | — | — | — | $18.7M | Compare |
| ESLAEstrella Immunopharma | $0.4101 | −7.53% | −67.7% | — | — | — | $17.8M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| CVMCel-Sci | $1.37 | −0.72% | −14.4% | — | — | — | $24.1M | Compare |
| JSPRJasper Therapeutics | $0.4692 | −8.20% | −48.3% | — | — | — | $15.6M | Compare |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| MGXMetagenomi Therapeutics | $0.7308 | −7.49% | −48.5% | −103.0% | — | — | $27.6M | Compare |
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
